A Novel Probiotic-antibiotic Combination to Prevent Recurrent Urinary Tract Infections

Conditions

• Recurrent Uti

Eligibility Criteria

Sex

ALL

Age

2 Years - 17 Years

Healthy Volunteers

Accepted

Interventions

• Saccharomyces Boulardii 250 MG [Florastor] — DRUG
  All patients will get the probiotic to be taken daily. If UTI occurs with a sensitive pathogen, we will treat with ciprofloxacin

Study Details

Patients with recurrent UTI were randomized to receive either the probiotic Sacchromyces Boulardii at enrollment, and the intracellularly active Ciprofloxacin with their first UTI episode after enrollment, or they received standard of care treatment.

Key Dates

Start date

Feb 2, 2022

Status verified

Jan 2025

Primary completion

Dec 31, 2024

Completion

Dec 31, 2025

Study Design

Enrollment

35 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Arms

• Experimental: Probiotic with or without antibiotic
  All patients will receive probiotics for this, only those with a UTI will get ciprofloxacin.
• No Intervention: Control
  Patients will get standard of care treatment.

Primary Outcome Measure

Reduction in UTI episodes [ Time Frame: 6 months ]

Central Contacts

• Mehreen Arshad, MD
  3122274080
  [email protected]

Locations (1)

Find similar trials in Chicago, IL